CAJ | 학술논문

为建立并获取更有效的乙肝疫苗，本实验通过将所构建的HBVRNA复制子疫苗和DNA疫苗分别免疫小鼠，检测细胞免疫与体液免疫的效果。结果表明，以pSFV为基础构建的疫苗载体免疫小鼠后采集的血清中抗体效价不随免疫剂量的增加而提高，在较低剂量免疫的时候，RNA复制子疫苗所产生的抗体效价优于DNA疫苗。并且RNA复制子疫苗在以较低剂量免疫后脾细胞CTL活性高于DNA疫苗。本研究证明HBVRNA疫苗比DNA疫苗表达效果更好，安全性更高，更具有应用前景。
위건립병획취경유효적을간역묘，본실험통과장소구건적HBVRNA복제자역묘화DNA역묘분별면역소서，검측세포면역여체액면역적효과。결과표명，이pSFV위기출구건적역묘재체면역소서후채집적혈청중항체효개불수면역제량적증가이제고，재교저제량면역적시후，RNA복제자역묘소산생적항체효개우우DNA역묘。병차RNA복제자역묘재이교저제량면역후비세포CTL활성고우DNA역묘。본연구증명HBVRNA역묘비DNA역묘표체효과경호，안전성경고，경구유응용전경。
To establish and obtain a more effective hepatitis B vaccine （HBV）, mice cellular and humoral immunity were detected and compared after being immunized by the RNA replicon vaccines and DNA vaccines of HBV which were constructed by our lab. The results showed that RNA replicon vaccines gained higher immune antibody titer, and higher CTL activity of spleen cells than that of DNA vaccines at low-dose, but not dose dependent. It was concluded that HBV RNA vaccines are much safer and gained higher expression efficiency than the DNA vaccines, thus RNA vaccines of HBV are more prospective for the gene therapy of HBV.